Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/1/2021
SIETES contiene 93213 citas

 
 
 1 a 20 de 106 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. U.S. Food and Drug Administration 2019:13 de diciembre. [Ref.ID 103231]
2.Enlace a cita original Cita con resumen
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Ballantyne CM, for the REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:3 de enero. [Ref.ID 102994]
3. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
4. Cita con resumen
Roehr B. Court rules that FDA cannot restrict off-label marketing. BMJ 2015;351:h4367. [Ref.ID 99403]
6. Cita con resumen
Anónimo. Icosapent ethyl (Vascepa) for severe hypertriglyceridemia. Med Lett Drugs Ther 2013;55:33-4. [Ref.ID 95656]
7. Cita con resumen
Anónimo. Drugs for hypertriglyceridemia. Med Lett Drugs Ther 2013;55:17-9. [Ref.ID 95162]
8. Cita con resumen
Lederle FA, Bloomfield HE. Drug treatment of asymptomatic hypertriglyceridemia to prevent pancreatitis: where is the evidence?. Ann Intern Med 2012;157:662-4. [Ref.ID 94014]
9.Tiene citas relacionadas Cita con resumen
Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardiff CM, Rudd JHF, Farkouh ME, Tawakol A, for the dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378:1547-59. [Ref.ID 91765]
10.Tiene citas relacionadas Cita con resumen
Stroes ESG, van Wijk DF. Dalcetrapib: turning the tide for CETP inhibition?. Lancet 2011;378:1529. [Ref.ID 91763]
11. Cita con resumen
Goldfine AB, Kaul S, Hiatt WR. Fibrates in the treatment of dyslipidemias - Time for a reassessment. N Engl J Med 2011;365:481-4. [Ref.ID 91479]
13. Cita con resumen
Krumholz H. Five lessons from Niaspan's dissappointing study. Journal Watch 2011;31:7 de junio. [Ref.ID 90732]
14. Cita con resumen
Anónimo. Everolimus and pazopanib: two new drugs for renal cell cancer. Med Lett Drugs Ther 2010;52:33-4. [Ref.ID 88491]
15.Tiene citas relacionadas
Varley C, McClellan J. Risks from antipsychotic medications in children and adolescents. In reply. JAMA 2010;303:730-1. [Ref.ID 87923]
16.Tiene citas relacionadas
Correll CU, Kane JM, Malhotra AK. Risks from antipsychotic medications in children and adolescents. In reply. JAMA 2010;303:730. [Ref.ID 87922]
17.Tiene citas relacionadas Cita con resumen
Lewin AB, Stroch EA, Storch HD. Risks from antipsychotic medications in children and adolescents. JAMA 2010;303:729-30. [Ref.ID 87921]
18.Tiene citas relacionadas Cita con resumen
Mangurian C, Fuentes-Afflick E, Newcomer JW. Risks from antipsychotic medications in children and adolescents. JAMA 2010;303:729. [Ref.ID 87920]
19.Tiene citas relacionadas Cita con resumen
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-73. [Ref.ID 86924]
20.Tiene citas relacionadas
Thompson WG, Gau GT. Hypertriglyceridemia and its pharmacologic treatment among US adults. Invited commentary. Arch Intern Med 2009;169:578-9. [Ref.ID 85598]
Seleccionar todas
 
 1 a 20 de 106 siguiente >>